Blockchain Registration Transaction Record

Tonix Pharmaceuticals Publishes Key TONMYA Study for Fibromyalgia Treatment

Tonix Pharmaceuticals publishes peer-reviewed study on FDA-approved TONMYA for fibromyalgia, detailing novel sublingual formulation's pharmacokinetics and improved tolerability profile for chronic pain management.

This news matters because it represents a significant advancement in chronic pain management, particularly for the millions of adults suffering from fibromyalgia who have had limited treatment options for over 15 years. The FDA approval and published research on TONMYA's novel sublingual formulation offer a non-opioid alternative that could transform patient care by providing durable pain relief with potentially better tolerability. For investors, it highlights Tonix's growing commercial presence and diverse pipeline across multiple therapeutic areas, while for the medical community, it provides valuable pharmacokinetic data supporting clinical use. The broader implications include potential applications of the technology for other CNS disorders and the company's contributions to national security through its DoD-funded infectious disease research.